A Pharmacoepidemiological Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice in Sweden.

Trial Profile

A Pharmacoepidemiological Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice in Sweden.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Acute coronary syndromes; Deep vein thrombosis; Stroke; Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 09 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 13 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top